ArticleScience (New York, N.Y.)2023
Mapping SARS-CoV-2 antigenic relationships and serological responses.
Open access · hybridAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
20.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 130 citations in OpenAlex.
- Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.Nature medicine · 2023Trial
- Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.Nature medicine · 2022Trial
- Report from the BV-BRC, CDC, NCBI, and NIAID Viral Sub-Species Classification Workshop.Journal of virology · 2026Article
- Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence.EBioMedicine · 2026Article
- SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination.iScience · 2026Article
- Post-pandemic changes in population immunity have reduced the likelihood of emergence of zoonotic coronaviruses.Nature communications · 2026Article
- Immunogenic relationship mapping supports a minimal-set trivalent vaccine strategy for broad sarbecovirus protection.Signal transduction and targeted therapy · 2026Article
- Article
- Integrated surveillance in Kilifi reveals continued SARS-CoV-2 circulation and immune escape of emerging JN.1 sublineages post-pandemic.Frontiers in cellular and infection microbiology · 2026Article
- SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi.PLOS global public health · 2026Article
- Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1.Nature communications · 2025Article
- Cross-neutralization of human sera with diverse SARS-CoV-2 omicron exposure histories, 2022-2024: Evidence of immune heterogeneity.One health (Amsterdam, Netherlands) · 2025Article
- A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023.Communications medicine · 2025Review
- Combining antigenic data from public sources gives an early indication of the immune escape of emerging virus variants.Scientific reports · 2025Article
- Article
- Multifunctional Polymer-Modified P-CaOPolymers · 2025Article
- Emergence of SARS-CoV-2 Omicron lineages shifted antibody-mediated protection curves.iScience · 2025Article
- Rapid Discovery of Potent Neutralizing Antibodies against SARS-CoV-2 through Directed Evolution of SARS-CoV-1 Antibodies.Molecular pharmaceutics · 2025Article
- Highly variable antigenic site located at the apex of GII.4 norovirus capsid protein induces cross-reactive blocking antibodies in a variant-specific manner.Journal of virology · 2025Article
- Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
32 authors at 13 institutions in 7 countries.
Samuel H Wilks *Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.ORCID 0000-0002-7760-8474
Barbara Mühlemann *Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.ORCID 0000-0002-5314-8530
Xiaoying Shen *Department of Surgery, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-8387-3952
Sina TüreliCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
Eric B LeGresleyCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.ORCID 0000-0002-5286-5693
Antonia NetzlCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.ORCID 0000-0001-8034-2382
Miguela A CanizaDepartment of Global Pediatric Medicine, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-7846-9605
Jesus N Chacaltana-HuarcayaHospital Nacional Daniel A. Carrión, Callao, Bellavista, Peru.ORCID 0000-0002-4235-5235
Victor M CormanInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.ORCID 0000-0002-3605-0136
Xiaoju DaniellDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-3706-9816
Michael B DattoDepartment of Pathology, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-9777-383X
Fatimah S DawoodCenters for Disease Control and Prevention, Atlanta, GA, USA.
Thomas N DennyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Christian DrostenInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.ORCID 0000-0001-7923-0519
Ron A M FouchierErasmus Medical Center, Rotterdam, Netherlands.ORCID 0000-0001-8095-2869
Patricia J GarciaSchool of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID 0000-0003-3874-2256
Peter J HalfmannInfluenza Research Institute, Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0002-1648-1625
Agatha JassemBC Centre for Disease Control, Vancouver, British Columbia, Canada.
Lara M JeworowskiInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.ORCID 0000-0002-4159-4189
Terry C JonesCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.ORCID 0000-0003-1120-9531
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0001-5061-8296
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-4121-776X
Charlene McDanalDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-4177-5561
Rolando PajonModerna, Inc., Cambridge, MA, USA.ORCID 0000-0002-5155-5079
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-6416-5096
Melissa S StockwellDivision of Child and Adolescent Health, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, and Department of Population and Family Health, Mailman School of Public Health, New York, NY, USA.ORCID 0000-0002-2113-7247
Haili TangDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Harm van BakelDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-1376-6916
Vic VeguillaCenters for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0002-0610-4316
Richard WebbyDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-4397-7132
David C MontefioriDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-0856-6319
Derek J SmithCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.ORCID 0000-0002-2393-1890
Duke University · USUniversity of Cambridge · GBHumboldt-Universität zu Berlin · DEIcahn School of Medicine at Mount Sinai · USCenters for Disease Control and Prevention · USSt. Jude Children's Research Hospital · USUniversity of Wisconsin–Madison · USBC Centre for Disease Control · CAColumbia University · USErasmus MC · NLModerna Therapeutics (United States) · USUniversidad Nacional del Callao · PEUniversidad Peruana Cayetano Heredia · PE
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MCollaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center75N93019C00050 · NIAID · DUKE UNIVERSITY · PI MOODY, TONY · 2019 to 2025
$69.1MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6MDissecting the drivers of persistent SARS-CoV-2 infectionsR01AI171569 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Viviana A Simon, Harm van Bakel · 2023 to 2026
$3.4MCOVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MNIAID NIH HHS 75N93019C00050NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI171569NIH HHS S10 OD026880NIH HHS S10 OD030463
Abstract
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, multiple variants escaping preexisting immunity emerged, causing reinfections of previously exposed individuals. Here, we used antigenic cartography to analyze patterns of cross-reactivity among 21 variants and 15 groups of human sera obtained after primary infection with 10 different variants or after messenger RNA (mRNA)-1273 or mRNA-1273.351 vaccination. We found antigenic differences among pre-Omicron variants caused by substitutions at spike-protein positions 417, 452, 484, and 501. Quantifying changes in response breadth over time and with additional vaccine doses, our results show the largest increase between 4 weeks and >3 months after a second dose. We found changes in immunodominance of different spike regions, depending on the variant an individual was first exposed to, with implications for variant risk assessment and vaccine-strain selection.
Indexed as
Antigens, ViralCOVID-19mRNA VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusAmino Acid SubstitutionAntibodies, NeutralizingAntibodies, ViralCross ReactionsHumansVaccinationAntibodies, NeutralizingAntibodies, ViralAntigens, ViralmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.